Advancement of extracellular vesicle therapy to the patient has been hampered by an inability to isolate extracellular vesicles in useful quantities while preserving their structural and functional integrity. EVs derived from MSCs enjoy the same nonimmunogenic characteristics of their parent cells. EVs processed using Aegle’s technology do not cause an adverse inflammation response in vivo, critical to the success of extracellular vesicle therapy.

Our preclinical research has shown that EVs isolated using traditional methods cause structural or functional damage to EVs, triggering a severe inflammation response and a complete lack of healing in porcine wound models. Using the same model, EVs isolated with our proprietary methodology accelerated healing, minimized and in some cases eliminated scarring and promoted blood vessel and nerve regeneration and hair growth.

Aegle’s technology allows for the production of therapeutic-grade extracellular vesicles from bone marrow derived MSCs. The ability to use extracellular vesicles in lieu of cells provides a means to harness the healing power of MSCs without the risk of cell proliferation or engraftment.